Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Disclosures
3. Outline of talk - vitamin D actions
4. Views of vitamin D actions - classical view
5. Calcium balance and bone homeostasis
6. Vitamin D and calcium are vital as estrogen drops
7. Vietnam AFC original crackers
8. Vitamin D metabolic pathways (1)
9. Views of vitamin D actions - expanded view
10. Vitamin D metabolic pathways (2)
11. Anti-cancer actions are highlighted in the press
12. Beneficial actions presented on a milk carton
13. Cancers in which vitamin D is protective
14. Outlline of talk - sunlight, vitamin D and PCa risk
15. Background: vitamin D and cancer
16. Risk factors and vitamin D deficiency hypothesis
17. PCa mortality rates and UV radiations in USA
18. Outline of talk - local calcitriol production
19. Vitamin D metabolic pathways (3)
20. Importance of local production of calcitriol
21. 2 alpha-hydroxylase activity in prostate cells
22. Growth inhibition of prostatic epithelial cells
23. 25(OH)D3 activity and 1 alpha-hydroxylase activity
24. Prostate synthesis of 1,25(OH)2D from 25(OH)D
25. Outline of talk - 24-hydroxylase activity level
26. Differential sensitivity to calcitriol actions
27. Liarozole
28. Inhibition of 24-hydroxylase activity by liarozole
29. Liarozole renders DU145 cells growth
30. Effect of liarozole on 1,25(OH)2D3 half life
31. VDR up-regulation by 1,25(OH)2D3 and liarozole
32. Conclusions: 24-hydroxylase inhibitors
33. Outline of talk - anti-cancer mechanisms
34. Mechanisms of anti-cancer activity of 1,25(OH)2D3
35. Vitamin D3 inhibits epithelial cells
36. Effect of 1,25(OH)2D3 on proliferation rate
37. Calcitriol and inflammation
38. COX-2 actions and prostate cancer
39. Inflammatory mechanisms in carcinogenesis
40. COX-2 and PG induction of cancer
41. Localization of COX-2 and recurrence probabilty
42. Search for new target genes regulated by calcitriol
43. Calcitriol exhibits three actions to inhibit PG action
44. Three calcitriol actions to inhibit PG activity
45. Calcitriol actions in PCa cells
46. Potential synergy of calcitriol with NSAIDs
47. Calcitriol and NSAIDs effects on PCa cells growth
48. Outline of talk - results of vitamin D therapy in vivo
49. Clinical trial of calcitriol and naproxen
50. Calcitriol plus naproxen trial
51. Change in PSADT
52. Conclusions
53. Progression from normal to PIA to PIN to PCa
54. Calcitriol inhibits PIN formation in Nkx3.2
55. Calcitriol blocks normal to high PIN conversion
56. ASCENT results: randomized, double-blind study
57. DN-101: ASCENT trial
58. ASCENT: duration of overall survival
59. Vitamin D role in prevention and treatment of PCa
60. Acknowledgements

Topics Covered

• Vitamin D actions: classical view and expanded view
• Vitamin D metabolic pathways
• Vitamin D and cancers
• Vitamin D-deficiency hypothesis
• Sunlight, vitamin D and prostate cancer risk
• Importance of local production of calcitriol
• Importance of 24-hydroxylase activity level
• Differential sensitivity to antiproliferative actions of calcitriol
• Inhibition of 24-hydroxylase activity by liarozole
• Anti-cancer mechanisms
• Calcitriol and inflammation
• COX-2 actions and prostate cancer
• Inflammatory mechanisms in carcinogenesis
• COX-2 and PG induction of cancer
• Three calcitriol actions to inhibit PG activity
• Potential synergy of calcitriol with NSAIDs
• Results of vitamin D therapy in in vivo trials of prostate cancer
• Calcitriol and naproxen
• Genetic mouse model of PIN-HG-PIN
• High dose intermittent calcitriol plus docetaxol

Links

Series:

• The World of Hormones

Categories:

• Cancer

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on December 1, 2007

Financial Disclosures

• Prof. David Feldman has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.